SCHEMBL6773776

SCHEMBL6773776

NN=CNc1cccc(C(=O)NCC(=O)NC(Cc2cccc(Br)c2)C(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 3/20 0.43
CTSS P25774 3/20 0.43
CTSK P43235 3/20 0.43
CTSL P07711 2/20 0.43
GLA P06280 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
GPR132 Q9UNW8 1/20 0.41
ITGB3 P05106 2/20 0.40
ITGB1 P05556 2/20 0.40
ITGAV P06756 2/20 0.40
ITGA5 P08648 2/20 0.40
MDM2 Q00987 2/20 0.40
POLB P06746 1/20 0.40
F10 P00742 1/20 0.40
F7 P08709 1/20 0.40
FPR2 P25090 2/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779571 0.91 FPR2 (0.43) NPC1RAB9AGAAGPR132ITGB3
SCHEMBL6775970 0.91 GPR132 (0.49) GPR132ITGB3ITGB1ITGAVITGA5
SCHEMBL6772224 0.90 CTSV (0.50) CTSBCTSSCTSKCTSLGPR132
SCHEMBL7838300 0.90 ITGB3 (0.51) CTSBCTSSCTSKCTSLGPR132
SCHEMBL7837213 0.89 CTSL (0.41) CTSLL3MBTL1GPR132ITGB3ITGB1
SCHEMBL3051751 0.89 GPR139 (0.44) CTSBCTSSCTSKCTSLGPR132
SCHEMBL7344058 0.88 GLA (0.41) CTSBCTSSCTSKCTSLGLA
SCHEMBL7345088 0.88 ITGB3 (0.41) GPR132ITGB3ITGB1ITGAVITGA5
SCHEMBL7823171 0.87 ITGB3 (0.50) GPR132ITGB3ITGB1ITGAVITGA5
SCHEMBL7345869 0.86 HTT (0.43) NPC1RAB9AGAAL3MBTL1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed